FDA-Approved Self-Collection HPV Tests Begin Shipping to Healthcare Facilities

The new tests aim to make cervical cancer screening more accessible and comfortable by allowing patients to collect their own samples.

Self-collection HPV tests approved by the FDA in May are now being shipped to doctors' offices.
The tests, developed by BD and Roche, enable patients to collect their own samples in healthcare settings.
This method is expected to reduce discomfort and increase screening rates, especially in underserved areas.
HPV is a leading cause of cervical cancer, which sees over 11,000 new cases annually in the U.S.
Future plans include making these tests available for at-home use, pending FDA approval.